30th Nov 2015 09:34
LONDON (Alliance News) - Biomedical and healthcare technology company NetScientific PLC on Monday said its ProAxsis portfolio company will present new data validating the use of the company's ProteaseTag Active Neutrophil Elastase Immunoassay in patients suffering with chronic obstructive pulmonary disease at an upcoming conference.
ProAxsis will present the data at the British Thoracic Society winter meeting on Thursday.
The ProteaseTags use smart molecules to trap active biomarkers of diseases. The test which will be presented measures Neutrophil Elastase, an important drug target and leading indicator of infection in patients with cystic fibrosis and COPD, NetScientific said.
Shares in NetScientific were down 5.8% to 105.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific